
Sign up to save your podcasts
Or


In 2025, the U.S. FDA removed the “black box” warnings from menopausal hormone therapy products – but what does that actually mean for patients? For decades, many women have navigated perimenopause and menopause with limited information, few effective options, and little validation of their symptoms. In part one of this two-part series, we speak with Sharon Malone, MD, board-certified OB-GYN and chief medical advisor for Alloy Women’s Health, about what happens during the menopausal transition, why symptoms can feel chaotic and unpredictable, and how misinterpretations of past research have shaped – and often restricted – women’s care.
Credits
See omnystudio.com/listener for privacy information.
By WebMD4.5
113113 ratings
In 2025, the U.S. FDA removed the “black box” warnings from menopausal hormone therapy products – but what does that actually mean for patients? For decades, many women have navigated perimenopause and menopause with limited information, few effective options, and little validation of their symptoms. In part one of this two-part series, we speak with Sharon Malone, MD, board-certified OB-GYN and chief medical advisor for Alloy Women’s Health, about what happens during the menopausal transition, why symptoms can feel chaotic and unpredictable, and how misinterpretations of past research have shaped – and often restricted – women’s care.
Credits
See omnystudio.com/listener for privacy information.

21,948 Listeners

43,510 Listeners

1,648 Listeners

1,417 Listeners

4,210 Listeners

112,945 Listeners

56,868 Listeners

6,447 Listeners

3,489 Listeners

9,275 Listeners

8,468 Listeners

6,447 Listeners

8,217 Listeners

6,443 Listeners

621 Listeners